

## Test Catalog

Diagnostic. Prognostic. Predictive. Predisposition.





### **NeoTYPE® GIST and Soft Tissue Tumor Profile**

#### **Alternative Name**

Soft Tissue Tumor Profile, Gastrointestinal Stromal Tumor Profile

#### Methodology

Molecular

#### **Test Description**

The NeoTYPE GIST/Soft Tissue Tumor Profile analyzes 43 biomarkers through a combination of next-generation sequencing (NGS), FISH, and IHC as listed below. Test orders include summary interpretation of all results to help guide treatment decisions. A microsatellite instability (MSI) NGS result of "indeterminate" will create a reflex to MSI by PCR as long as the tumor percentage is ?40% and paired normal tissue is available.

- NGS (38 genes + 2 biomarkers): AKT1, AKT2, AKT3, ARID1A, ATM, BRAF, CDKN2A, CTNNB1, ERBB2, ERBB4, FGFR1, FGFR2, FGFR3, GNAS, HRAS, KIT, KRAS, MAP2K1, MET, Microsatellite Instability (MSI), NF1, NRAS, NTRK1 fusions, NTRK2 fusions, NTRK3 fusions, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, SDHA, SDHB, SDHC, SDHD, SMAD4, SMO, SRC, TERT Promoter, TP53, Tumor Mutation Burden (TMB)
- FISH (2 FISH): MET, PTEN (tech-only available)
- IHC (1 biomarker): PD-L1 LDT (tech-only available)

#### **Clinical Significance**

The GIST and Soft Tissue Tumor Profile characterizes primary or metastatic gastrointestinal stromal tumors, sarcomas, and other soft tissue primary or metastatic tumors of any histological subtype for the most significant genetic changes relevant to therapy decisions, prognosis, and clinical research. It is appropriate for patients with newly-diagnosed or recurrent disease, patients with an atypical clinical presentation, and patients with resistant disease to explore options in clinical trials.

#### **Specimen Requirements**

• FFPE tissue: Paraffin block preferred. Please use 10% buffered formalin fixative. Do not use zinc fixatives.

#### **Storage & Transportation**

Use cold pack for transport, making sure cold pack is not in direct contact with specimen.

#### CPT Code(s)\*

81445x1, 88377x2, 88360x1

#### Medicare MoIDX CPT Code(s)\*

81479

#### **New York Approved**

Yes

# **Level of Service** Global **Turnaround Time** 14 days

Please direct any questions regarding coding to the payor being billed.

<sup>\*</sup>The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, and immunohistochemistry through our nation-wide network of CAP-accredited, CLIA-certified laboratories.

Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publications with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information.

\*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.



9490 NeoGenomics Way Fort Myers, FL 33912

Phone: 239.768.0600/ Fax: 239.690.4237

neogenomics.com

© 2024 NeoGenomics Laboratories, Inc. All Rights Reserved. All other trademarks are the property of their respective owners

Rev. 112324